Grace Therapeutics (GRCE)
NASDAQ:GRCE
Want to see GRCE full AI Analyst Report?
Total Valuation
Grace Therapeutics has a market cap or net worth of $38.73M. The enterprise value is $15.68M.
Market Cap$38.73M
Enterprise Value$15.68M
Share Statistics
Grace Therapeutics has 16,274,027 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding16,274,027
Owned by Insiders8.06%
Owned by Institutions10.90%
Financial Efficiency
Grace Therapeutics’s return on equity (ROE) is -0.12 and return on invested capital (ROIC) is -14.10%.
Return on Equity (ROE)-0.12
Return on Assets (ROA)-0.12
Return on Invested Capital (ROIC)-14.10%
Return on Capital Employed (ROCE)-0.17
Revenue Per Employee0.00
Profits Per Employee-1.95M
Employee Count4
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Grace Therapeutics is ―. Grace Therapeutics’s PEG ratio is 0.17.
PE Ratio―
PS Ratio0.00
PB Ratio1.20
Price to Fair Value1.20
Price to FCF-8.62
Price to Operating Cash Flow-4.42
PEG Ratio0.17
Income Statement
In the last 12 months, Grace Therapeutics had revenue of 0.00 and earned -7.79M in profits. Earnings per share was -0.47.
Revenue0.00
Gross Profit0.00
Operating Income-11.08M
Pretax Income-9.49M
Net Income-7.79M
EBITDA-11.07M
Earnings Per Share (EPS)-0.47
Cash Flow
In the last 12 months, operating cash flow was -8.88M and capital expenditures 0.00, giving a free cash flow of -8.88M billion.
Operating Cash Flow-8.88M
Free Cash Flow-8.88M
Free Cash Flow per Share-0.55
Dividends & Yields
Grace Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.22
52-Week Price Change-19.87%
50-Day Moving Average2.53
200-Day Moving Average3.28
Relative Strength Index (RSI)49.38
Average Volume (3m)58.56K
Important Dates
Grace Therapeutics upcoming earnings date is Aug 6, 2026, TBA (Confirmed).
Last Earnings DateJun 18, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
Grace Therapeutics as a current ratio of 8.10, with Debt / Equity ratio of 0.00%
Current Ratio8.10
Quick Ratio8.10
Debt to Market Cap0.00
Net Debt to EBITDA1.53
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Grace Therapeutics has paid -1.70M in taxes.
Income Tax-1.70M
Effective Tax Rate0.18
Enterprise Valuation
Grace Therapeutics EV to EBITDA ratio is -5.37, with an EV/FCF ratio of -6.71.
EV to Sales0.00
EV to EBITDA-5.37
EV to Free Cash Flow-6.71
EV to Operating Cash Flow-6.71
Balance Sheet
Grace Therapeutics has $16.98M in cash and marketable securities with $0.00 in debt, giving a net cash position of $16.98M billion.
Cash & Marketable Securities$16.98M
Total Debt$0.00
Net Cash$16.98M
Net Cash Per Share$1.04
Tangible Book Value Per Share$0.89
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Grace Therapeutics is $6.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$6.00
Price Target Upside30.43% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast43.67%